Theseus Pharmaceuticals Inc

Theseus Pharmaceuticals — Investor Presentation (March 2022)

31 slides from Theseus Pharmaceuticals's investor presentation, Mar 10, 2022

  1. Slide 1: A new generation of medicines to address cancer resistance

    Theseus Pharmaceuticals A new generation of medicines to address cancer resistance March 2022 THRX ​ ​

  2. Slide 2: Legal notice and forward-looking statements

    Legal notice and forward-looking statements 2 ©2022 Theseus Pharmaceuticals. This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regardi

  3. Slide 3: Theseus – working to outsmart cancer resistance

    Theseus – working to outsmart cancer resistance 3 ©2022 Theseus Pharmaceuticals. Pan-variant inhibitors: Therapeutics that inhibit all major genetic variants arising in an oncogenic target that cause resistance to cancer treatments Led by scientific team from ARIAD Differentiated, predictive R&D app

  4. Slide 4: World class management team

    Bill Shakespeare, PhD Co-founder, President of R&D Former VP Drug Discovery, ARIAD World class management team Vic Rivera, PhD Co-founder, CSO Former VP Preclinical & Translational Research, ARIAD David Dalgarno, D. Phil Co-founder, CTO Former VP Research Technologies, ARIAD David Kerstein, MD CMO F

  5. Slide 5: Prior success at ARIAD validates pan-variant approach

    TKI Target IND Filing Approval Pan-BCR-ABL 2007 2012 Pan-ALK 2011 2017 EGFR-ex20 2015 2021 Prior success at ARIAD validates pan-variant approach 5 ©2022 Theseus Pharmaceuticals. Members of Theseus team discovered and developed five clinical-stage product candidates at ARIAD, including three approved

  6. Slide 6: Resistance mutations hamper cancer treatment

    Resistance mutations hamper cancer treatment 6 ©2022 Theseus Pharmaceuticals. The Problem: Resistance Mutations The solution: The Power of ‘Pan’ Therapeutics with pan-variant coverage have a broad range of activity against all genetic variants that have been shown to contribute to treatment resistan

  7. Slide 7: The Theseus Strategy

    The Theseus Strategy 7 Identify clinically validated targets with clear unmet need Structure-guided drug design with predictive screening methodologies Translationally-driven, biomarker-guided clinical development ©2022 Theseus Pharmaceuticals. ​ ​

  8. Slide 8: Research and discovery approach

    Cell-based assay with human serum proteins; mimics the physiological environment Guides development of pan-variant inhibitors Helps predict clinical outcomes for TKIs in the context of anticipated mutations Extensive experimental and computational analysis to optimize ‘pan-ness’ Research and discove

  9. Slide 9: Our pipeline

    Several potential targets in research and discovery Our pipeline 9 ©2022 Theseus Pharmaceuticals. Note: We hold a worldwide exclusive license to THE-630 in our therapeutic area of focus through the ARIAD License Agreement, as defined and described in the section titled “Business—ARIAD License Agreem

  10. Slide 10: THE-630: Pan-KIT Inhibitor

    THE-630: Pan-KIT Inhibitor ​ ​

  11. Slide 11: Gastrointestinal stromal tumors (GIST) overview

    Gastrointestinal stromal tumors (GIST) overview 11 ©2022 Theseus Pharmaceuticals. Key features of GIST Genetics of primary sensitivity and secondary resistance are well understood Remains KIT-driven through multiple lines of therapy Tumor heterogeneity: patients’ tumors frequently have multiple subc

  12. Slide 12: GIST: Activating and resistance mutations in KIT

    Gastrointestinal stromal tumors (GIST): Activating and resistance mutations in KIT 12 ©2022 Theseus Pharmaceuticals. Activating Mutations drive tumor development KIT oncoprotein Exon 9 (10%) Exon 11 (70%) Exon 13-14 (~45%) ATP Binding Pocket Exon 17-18 (~45%) Activation loop Resistance Mutations ena

  13. Slide 13: Current limitations of GIST treatment options create significant unmet medical need

    Current limitations of GIST treatment options create significant unmet medical need 13 ©2022 Theseus Pharmaceuticals. Line Therapy Objective Response Rate Median Progression-Free Survival (Months) 1st Imatinib 51.4% 18.9 2nd Sunitinib 6.8% 5.5 3rd Regorafenib 4.5% 4.8 4th Ripretinib 9.4% 6.3 Treatme

  14. Slide 14: PRA predicts the deficiencies of current GIST therapies

    PRA predicts the deficiencies of current GIST therapies 14 ©2022 Theseus Pharmaceuticals. Note: Cav is calculated as the Area Under the Curve, or AUC, over a 24-hour period and divided by 24 PRA activity of approved TKIs against KIT activation and resistance mutations PRA predicts that in GIST, mult

  15. Slide 15: None of the available GIST therapies are pan-KIT inhibitors

    None of the available GIST therapies are pan-KIT inhibitors 15 ©2022 Theseus Pharmaceuticals. Note: PR/CR means partial/complete response; SD means stable disease; PD means progressive disease Therapy PRA-Predicted Best Response Activating Mutations Resistance Mutations Therapy Exon 9 Exon 11 Exon 1

  16. Slide 16: PRA predicts that THE-630 has pan-KIT activity

    PRA predicts that THE-630 has pan-KIT activity 16 ©2022 Theseus Pharmaceuticals. Therapy PRA Predicted Response Activating Mutations Resistance Mutations Therapy Exon 9 Exon 11 Exon 13-14 ATP Binding Pocket Exon 17-18 Activation Loop Imatinib Sunitinib Regorafenib Ripretinib THE-630* *Based on 100 n

  17. Slide 17: THE-630 has the profile of a pan-KIT inhibitor for GIST in vivo

    Vehicle, qd the-630, 20 mg/kg QD vehicle, bid ripretinib, 50 mg/kg BID THE-630 has the profile of a pan-KIT inhibitor for GIST in vivo 17 Ripretinib: Strong anti-tumor activity against activation loop (D820A/Ex17) but not ATP binding pocket (V654A/Ex13) mutations THE-630: Strong anti-tumor activity

  18. Slide 18: THE-630 PK supports once-daily oral dosing

    THE-630 PK supports once-daily oral dosing Orally bioavailable across multiple species – mice, rats and NHPs In primate PK studies, target plasma levels of THE-630 sustained above 100nM 18 ©2022 Theseus Pharmaceuticals. ​ ​

  19. Slide 19: Kinome Selectivity; toxicology studies support clinical evaluation of THE-630

    Kinome Selectivity Results of toxicology studies support clinical evaluation of THE-630 19 Designed to avoid off-target effects Kinome selectivity in vitro comparable to the approved KIT inhibitor ripretinib No drug-drug interactions or cardiac toxicity liabilities identified in standard pharmacolog

  20. Slide 20: Phase 1/2 dose escalation and dose expansion trial design

    Phase 1/2 dose escalation and dose expansion trial design 20 ©2022 Theseus Pharmaceuticals. Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Dose Level X Expansion at RP2D Phase 2 Expansion in Patients with GIST (Cohorts Defined by Prior Therapy) 5L+ GIST (prior imatinib, sunitinib, regorafenib a

  21. Slide 21: Registration strategy for THE-630

    Registration strategy for THE-630 21 ©2022 Theseus Pharmaceuticals. Based on data from the planned Phase 1/2 trial in patients with advanced GIST and regulatory feedback we intend to commence a registration trial in fifth-line GIST followed by the initiation of a registration trial in second-line GI

  22. Slide 22: Fourth-Generation EGFR Inhibitor

    Fourth-Generation EGFR Inhibitor ​ ​

  23. Slide 23: Lung cancer and the role of EGFR

    Lung cancer and the role of EGFR 23 ©2022 Theseus Pharmaceuticals. ~2.2 million New cases diagnosed globally in 2020 NSCLC is the most common form of lung cancer ~85% Percentage of lung cancers diagnosed as NSCLC EGFR mutations are a leading driver of NSCLC up to 50% NSCLC tumors driven by activatin

  24. Slide 24: EGFR-mutant NSCLC shows resistance to current therapy

    EGFR-mutant NSCLC shows resistance to current therapy 24 ©2022 Theseus Pharmaceuticals. DC LC 3rd Gen Osimertinib 1st & 2nd Gen T790M (T) DT LT C797S (C) DTC LTC Mutations that arise from therapy Resistance mutations in EGFR emerge that contribute to NSCLC patients’ progression on osimertinib up to

  25. Slide 25: Theseus target product profile

    Theseus target product profile 25 ©2022 Theseus Pharmaceuticals. Activity against Wild Type Selectivity over Central Nervous System (CNS)-active Eventually, NSCLC will relapse with disease in the brain Permeability into Theseus target product profile D L DC LC DT LT DTC LTC ​ ​

  26. Slide 26: Novel series exhibit potent EGFR mutant activity with selectivity over wild type

    Novel series exhibit potent EGFR mutant activity in cells with selectivity over wild type 26 ©2022 Theseus Pharmaceuticals. Theseus compounds demonstrated low nanomolar IC50 values against single-, double- and triple-mutant EGFR variants, with selectivity over WT EGFR Development candidate nominatio

  27. Slide 27: Novel series shows in vivo anti-tumor activity in triple-mutant DTC model

    Novel series shows in vivo anti-tumor activity in triple- mutant DTC model 27 ©2022 Theseus Pharmaceuticals. Theseus compounds exhibited strong anti-tumor activity in DTC model at doses well-tolerated in mice Note: QD is once daily dosing EGFR DTC Triple Mutant days post treatment mean tumor volume

  28. Slide 28: Theseus Compound B demonstrates strong anti-tumor activity in vivo

    Theseus Compound B demonstrates strong anti-tumor activity against single(L)-, double(LT)-, and triple(LTC)-mutant EGFR variants in vivo 28 ©2022 Theseus Pharmaceuticals. Note: QD is once daily dosing. TR is Tumor Regression. TGI is Tumor Growth Inhibition Intracranial mouse models to assess CNS act

  29. Slide 29: Roadmap to success

    Roadmap to success 29 ©2022 Theseus Pharmaceuticals. Multiple near-term inflection points Team to succeed Importance of ‘Pan’ Phase 1/2 clinical trial actively enrolling; Phase 1 commenced with first-patient-dosed in January 2022; initial data expected in 1H 2023 DC nomination expected in Q3 2022 fo

  30. Slide 30: Theseus – working to outsmart cancer resistance

    Theseus – working to outsmart cancer resistance 30 ©2022 Theseus Pharmaceuticals. Pan-variant inhibitors: Therapeutics that inhibit all major genetic variants arising in an oncogenic target that cause resistance to cancer treatments Led by scientific team from ARIAD Differentiated, predictive R&D ap

  31. Slide 31: © THESEUS

    © THESEUS

Theseus Pharmaceuticals — Investor Presentation (March 2022) on 6ix